Beatch G N, Davis D R, Laganière S, Williams B A
Bureau of Drug Research, Health Protection Branch, Department of Health Canada.
J Cardiovasc Pharmacol. 1996 Nov;28(5):618-30. doi: 10.1097/00005344-199611000-00003.
Our objective was to define the actions of sematilide in rabbits and to assess the contribution of the delayed rectifier (IK) to rate dependence of action potential duration (APD) in rabbit ventricular myocardium. In studies in vivo, New Zealand White rabbits were used to obtain dose/response curves of the effects of sematilide on APD from contact monophasic action potentials (MAP), ventricular effective refractory period (VERP), and ECG. Sematilide or placebo was administered as an i.v. bolus followed by a 45-min infusion in the following cumulative manner: infusion 1 (1 mg/kg bolus + 8 micrograms/kg/min); infusion 2 (2 mg/kg + 20 micrograms/kg/min); and infusion 3 (7 mg/kg + 68 micrograms/kg/min). At each infusion level, VERP and APD at 75% repolarization (APD75) were measured during cardiac pacing between 200- and 400-ms cycle length (CL). Serum sematilide levels were analyzed by high-performance liquid chromatography (HPLC). In studies in vitro, sematilide's effects on the delayed rectifier were assessed in isolated rabbit ventricular myocytes by using patch-clamp techniques. Sematilide infusion in vivo resulted in stable serum levels of 1.3 +/- 0.5, 3.7 +/- 1.4, and 13.4 +/- 1.8 micrograms/ml during infusions 1, 2, and 3, respectively. Maximal effects occurred at infusion 2, such that at 400 ms CL, sematilide widened predrug APD75 (145 +/- 5 ms) by 27 +/- 4% (p < 0.001 vs. placebo), and at 200-ms CL, sematilide prolonged predrug APD75 (115 +/- 10 ms) by only 18 +/- 4% (p < 0.001 vs. placebo; p < 0.05 vs. 400-ms CL). Similar effects were observed in VERP. Sematilide enhanced rate dependence of APD and produced the same degree of APD prolongation at a given CL, during accommodation to and recovery from rapid pacing. Rabbit ventricular myocytes appeared to have at least two types of delayed rectifier. Sematilide selectively blocked IKr, and block was not relieved by repetitive stimulation. In conclusion, the APD-widening effect of sematilide was independent of previous pacing history. Sematilide had little influence on background processes likely responsible for shortening APD because of rapid repetitive stimulation.
我们的目的是确定司美利特在兔体内的作用,并评估延迟整流钾电流(IK)对兔心室肌动作电位时程(APD)频率依赖性的贡献。在体内研究中,使用新西兰白兔通过接触式单相动作电位(MAP)、心室有效不应期(VERP)和心电图来获得司美利特对APD作用的剂量/反应曲线。司美利特或安慰剂以静脉推注给药,随后以以下累积方式进行45分钟输注:输注1(1mg/kg推注+8μg/kg/min);输注2(2mg/kg+20μg/kg/min);输注3(7mg/kg+68μg/kg/min)。在每个输注水平,在200至400毫秒心动周期长度(CL)的心脏起搏期间测量VERP和复极化75%时的APD(APD75)。通过高效液相色谱法(HPLC)分析血清司美利特水平。在体外研究中,使用膜片钳技术评估司美利特对兔离体心室肌细胞延迟整流钾电流的作用。在体内输注司美利特期间,输注1、2和3时血清水平分别稳定在1.3±0.5、3.7±1.4和13.4±1.8μg/ml。最大效应出现在输注2时,因此在400毫秒CL时,司美利特使给药前的APD75(145±5毫秒)增宽27±4%(与安慰剂相比,p<0.001),在200毫秒CL时,司美利特使给药前的APD75(115±10毫秒)仅延长18±4%(与安慰剂相比,p<0.001;与400毫秒CL相比,p<0.05)。在VERP中观察到类似的效应。司美利特增强了APD的频率依赖性,并在适应快速起搏和从快速起搏恢复期间,在给定CL下产生相同程度的APD延长。兔心室肌细胞似乎至少有两种类型的延迟整流钾电流。司美利特选择性阻断IKr,且重复刺激不能解除阻断。总之,司美利特的APD增宽效应与先前的起搏史无关。司美利特对可能因快速重复刺激而导致APD缩短的背景过程影响很小。